National General Holdings Corp. Reports Third Quarter 2017 Results
Nov 08, 2017 21:05 pm UTC| Business
NEW YORK, Nov. 08, 2017 -- National General Holdings Corp. (NASDAQ:NGHC) today reported third quarter 2017 net income of $46.2 million or $0.43 per diluted share, compared to net income of $19.9 million or $0.18 per...
Ovid Therapeutics to Participate at the Stifel 2017 Healthcare Conference
Nov 08, 2017 21:05 pm UTC| Business
NEW YORK, Nov. 08, 2017 -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines for patients with rare neurological disorders, today announced that Jeremy Levin, DPhil, MB...
Hallmark Financial Services, Inc. Announces Third Quarter 2017 Results
Nov 08, 2017 21:05 pm UTC| Business
FORT WORTH, Texas, Nov. 08, 2017 -- Hallmark Financial Services, Inc. (NASDAQ:HALL) today announced results for its third fiscal quarter ended September 30, 2017, including the following highlights: 3rd quarter 2017...
BlackLine Announces Financial Analyst Day
Nov 08, 2017 21:05 pm UTC| Business
LOS ANGELES, Calif., Nov. 08, 2017 -- BlackLine, Inc. (Nasdaq:BL) announced today that it will host its financial analyst day on Wednesday, Nov. 15, 2017 in Los Angeles at 12:00 p.m. Pacific Time / 3:00 p.m. Eastern...
REGENXBIO Reports Third Quarter 2017 Financial Results and Recent Operational Highlights
Nov 08, 2017 21:05 pm UTC| Business
Completed second cohort dosing in RGX-314 Phase I clinical trial for wet AMDCompleted first cohort dosing in RGX-501 Phase I/II clinical trial for HoFHInterim trial updates to be included in the Company’s year-end 2017...
Novavax to Present at the Stifel 2017 Healthcare Conference
Nov 08, 2017 21:05 pm UTC| Business
GAITHERSBURG, Md., Nov. 08, 2017 -- Novavax, Inc., (Nasdaq:NVAX) today announced the Company will present at the Stifel 2017 Healthcare Conference. Presentation details are as follows: Date: Wednesday, November 15,...
miRagen Therapeutics Reports Third Quarter 2017 Financial Results and Provides Corporate Update
Nov 08, 2017 21:05 pm UTC| Business
MRG-106 Phase 1 trial expanded to include additional oncology indications, enrollment commencedMRG-201 expected to advance into a Phase 2a trial in cutaneous fibrosis in the first half of 2018MRG-110 on track to complete...